Given the data from the current study as well as published work, there is a strong rationale for clinical development of PD 0332991 focusing on ER-positive luminal breast cancer as well as HER2-amplified disease and combining CDK4/6 inhibition with anti-estrogen or anti-HER2 therapy, respectively. The gene discussed is CDK4; the disease is breast carcinoma.